Member Info for busicat

Cat out of bag scenario behind price moves?

A tariff-world masterstroke:

"Our deliberate strategy of "manufacture in the region, for the region" - combining regional resilience with globally consistent quality and service - positions the Group to react quickly and effectively to geopolitical shifts, trade barriers, and evolving customer requirements."

Another example I have in mind is Currys, which sank to under 50p for March 2023, only to steadily recover to over 100p so far. But those months in the doldrums seemed a long wait.

I was just noticing that trade and seeing 1,329k also seemingly bought on Tues at 1.48p, and a 1,360k trade yesterday (price and buy/sell unclear). Could mean absolutely nothing, but I'm interested to see if there's more...

Today's price not helped I think by two transactions at the 69p rate all others seemed to be selling at before and after this print out:

24-Apr-25 10:37:17 69.00 200,000 Buy* 68.40 69.10 138.00k O

24-Apr-25 10:37:17 69.00 200,000 Buy* 68.40 69.10 138.00k O

35% drop seems overdone?!

Seeing this led me to ask the internet about the differences between GDR and Genomadix, since both have NICE greenlight (albeit, the latter is for when Gendrive not available...):

"Genedrive uses a point-of-care (POC) test that can detect more CYP2C19 alleles and doesn't require cold storage, while Genomadix's Cube test, while also a POC test, has limitations in the number of alleles it detects and requires cold storage."

Not news to many here, but news to me!

Thanks to slock for adding comments on the Investor Meet. Sorry to see it wasn't more inspiring!

Slock, any other observations on the Investor Meet?

I wonder why so hard to buy today... I only asked for a few and still no fill

Not really sure. But the series of buys at higher rounded numbers makes me think someone with deeper pockets than me has faith in the management statement that "The Group enters 2025 with renewed optimism as several, potentially significant, market opportunities start to gain momentum."

On the other hand, it seems that it doesn't take much for smaller investors taking the chance to exit to to take the steam out of the rise!

Interesting to look out for progress here. A few points encouraging me to dip a toe in despite recent falling price:

At the start of commercialisation with good progress on existing customer projects

December succesful raise of £6.3m (target £6m) to fund project delivery.

Commissioning team expansion with Senior Process Commissioning Engineer in last few weeks. Job advert said "Our technology platforms have caught the attention of many organisations both here in the UK and overseas.

As a result, we are looking to expand our engineering design team to develop and scale-up our Membrane-Free Electrolysers."

Interesting large buying volume for this one keeping the price higher than I expected for now...

As price now seems to been in steady recovery mode from the depths, I think today's RNS gives further context as well as various posts here, including JeremyCC's handy 19 March summary of SAG holdings changes

The full year results will be published on Tuesday 25th March 2025, so question is whether to dare a top up on Monday!

I thought you were right, StM, but luckily didn't follow up with a top up!

Up 3.5% in US at close, whilst Hang Seng minus 1.98% currently. I'm trusting the former is the better indicator for PRU today...

US up 2.82% 15mins ago seems to have given us another run up closer to £8 over here. I wonder if the same retreat will occur as we saw this morning.

Also the 420p new target from Berenberg, up from their increase from 270p to 330p in January in response to the trading update suggests their analysts see the results and outlook as much more positive the trading update had indicated. (Yes, I know we all think analyst targets are worthless. But they will have looked more closely at the financials and prospects than me, so I'm happy to take their conclusion as a positive sign.)

The price fall on great 2024 results looks overdone to me. Presumably market expectations were higher, but 2025 guidance in the 2024 results report (copied below) indicates continued positive moment.

Today's buys by the Chair of £ 84,563.24 invested at 247.97p and by a NED investing £24,860.62 at 235.82 suggest insiders think the fall unjustified.

2025 prospects:

"2024 bookings growth supports our ability to deliver high-teens constant currency revenue

growth for the current year

At current rates, FX may be a headwind

Adjusted EBITDA expected to be slightly ahead of market expectations*

Expect 2ppt YoY margin improvement

Confident in consistently delivering mid-teens revenue growth and operating leverage over the long term"